Innoviva Debt to Equity Ratio 2006-2020 | INVA

Current and historical debt to equity ratio values for Innoviva (INVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Innoviva debt/equity for the three months ending March 31, 2020 was 0.93.
Innoviva Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2020-03-31 $0.38B $0.41B 0.93
2019-12-31 $0.38B $0.34B 1.10
2019-09-30 $0.39B $0.28B 1.37
2019-06-30 $0.39B $0.25B 1.57
2019-03-31 $0.39B $0.20B 1.93
2018-12-31 $0.38B $0.16B 2.41
2018-09-30 $0.38B $-0.11B -3.52
2018-06-30 $0.49B $-0.16B -3.13
2018-03-31 $0.49B $-0.21B -2.28
2017-12-31 $0.57B $-0.24B -2.37
2017-09-30 $0.58B $-0.22B -2.59
2017-06-30 $0.64B $-0.30B -2.15
2017-03-31 $0.70B $-0.33B -2.10
2016-12-31 $0.71B $-0.35B -2.01
2016-09-30 $0.72B $-0.37B -1.96
2016-06-30 $0.72B $-0.36B -1.99
2016-03-31 $0.74B $-0.36B -2.03
2015-12-31 $0.73B $-0.34B -2.14
2015-09-30 $0.74B $-0.32B -2.30
2015-06-30 $0.74B $-0.29B -2.51
2015-03-31 $0.73B $-0.26B -2.81
2014-12-31 $0.73B $-0.22B -3.25
2014-09-30 $0.71B $-0.19B -3.65
2014-06-30 $0.74B $-0.19B -3.93
2014-03-31 $0.29B $0.26B 1.09
2013-12-31 $0.29B $0.30B 0.96
2013-09-30 $0.29B $0.33B 0.87
2013-06-30 $0.46B $0.09B 5.37
2013-03-31 $0.46B $0.09B 5.03
2012-12-31 $0.17B $0.16B 1.11
2012-09-30 $0.17B $0.17B 1.00
2012-06-30 $0.17B $0.19B 0.91
2012-03-31 $0.17B $0.01B 28.14
2011-12-31 $0.17B $-0.09B -1.98
2011-09-30 $0.17B $-0.06B -2.92
2011-06-30 $0.17B $-0.04B -4.60
2011-03-31 $0.17B $-0.03B -6.20
2010-12-31 $0.17B $-0.02B -7.70
2010-09-30 $0.17B $-0.14B -1.22
2010-06-30 $0.17B $-0.13B -1.37
2010-03-31 $0.17B $-0.11B -1.53
2009-12-31 $0.17B $-0.19B -0.91
2009-09-30 $0.17B $-0.18B -0.99
2009-06-30 $0.17B $-0.16B -1.08
2009-03-31 $0.17B $-0.14B -1.20
2008-12-31 $0.17B $-0.14B -1.28
2008-09-30 $0.17B $-0.13B -1.38
2008-06-30 $0.17B $-0.11B -1.55
2008-03-31 $0.17B $-0.09B -1.91
2007-12-31 $0.00B $-0.07B -0.01
2007-09-30 $0.00B $-0.04B -0.01
2007-06-30 $0.00B $-0.02B -0.03
2007-03-31 $0.00B $0.02B 0.03
2006-12-31 $0.00B $0.06B 0.01
2006-09-30 $0.00B $0.09B 0.01
2006-06-30 $0.00B $0.13B 0.01
2006-03-31 $0.00B $0.16B 0.00
2005-12-31 $0.00B $0.06B 0.01
2005-09-30 $0.00B $0.10B 0.01
2005-06-30 $0.00B $0.13B 0.01
2005-03-31 $0.00B $0.16B 0.01
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.398B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $376.694B 16.10
Roche Holding AG (RHHBY) Switzerland $300.546B 0.00
Novartis AG (NVS) Switzerland $202.458B 15.82
Merck (MRK) United States $200.868B 14.55
Pfizer (PFE) United States $191.697B 11.90
Eli Lilly (LLY) United States $159.622B 25.83
Novo Nordisk (NVO) Denmark $155.228B 25.85
AbbVie (ABBV) United States $146.212B 10.74
AstraZeneca (AZN) United Kingdom $141.979B 29.24
Sanofi (SNY) $130.716B 15.13
GlaxoSmithKline (GSK) United Kingdom $102.874B 12.28
Bayer (BAYRY) Germany $70.538B 10.06
H Lundbeck (HLUYY) Denmark $7.848B 13.64